Multiple Sclerosis (MS) Research Reports
| Relapsing Multiple Sclerosis (RMS) – Pipeline Review, H1 2013 Topics: Multiple Sclerosis (MS), Drug Discovery |
| PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: France |
| PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Italy |
| PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: United Kingdom |
| PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Japan |
| PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Canada |
| PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: United States |
| PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Germany |
| PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Spain |
| PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: India |
| PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: China |
| PharmaPoint: Multiple Sclerosis - Current and Future Players Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery |
| Multiple Sclerosis – Pipeline Review, H1 2013 Topics: Multiple Sclerosis (MS), Drug Discovery |
| Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H1 2013 Topics: Multiple Sclerosis (MS), Drug Discovery |
| Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Germany |
| Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Siponimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Tcelna (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: United States |
| Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: France |
| Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Italy |
| Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Drug Discovery Regions: Spain |
| Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: United Kingdom |
| Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Japan |
| Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: India |
| Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: China |
| Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery Regions: Canada |
| Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Topics: Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
| Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H1 2013 Topics: Multiple Sclerosis (MS), Drug Discovery |
| EpiCast Report: Multiple Sclerosis Epidemiology Forecast to 2022 Topics: Multiple Sclerosis (MS) Regions: Global |
| TreatmentTrends®: Multiple Sclerosis (EU) 2012 Topics: Multiple Sclerosis (MS), Research & Development, Clinical Trial |
| Multiple Sclerosis Topics: Multiple Sclerosis (MS), Drug Discovery |
| Disease and Therapy Review: Multiple Sclerosis Topics: Multiple Sclerosis (MS), Drug Discovery, CNS/Neurology Regions: Global |
| ChartTrends®: Multiple Sclerosis (US) 2012 Topics: Multiple Sclerosis (MS), Prescription Drugs Regions: United States |
| Market and Product Forecasts: Top 10 Neurology Brands: 2011–21 Topics: Multiple Sclerosis (MS), Pharmaceuticals Company Reports, Manufacturing, Packaging & Detailing, CNS/Neurology |
| Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments Topics: Alzheimer's Disease, Hepatitis, Parkinson's Disease, Multiple Sclerosis (MS), Vaccines, Pediatrics, Cancer Vaccines, Pandemic Vaccines Regions: Global |
| TreatmentTrends®: Multiple Sclerosis (US) Q3 2012 Topics: Multiple Sclerosis (MS), Prescription Drugs Regions: United States |
| Market and Product Forecasts: Top 10 Neurology Brands 2011–21 Topics: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis (MS), Research & Development, Drug Discovery, CNS/Neurology |
Prev | 1 | 2 | Next
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.